This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1 through R6 are as defined in the specification
These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.
[EN] SPIROCYCLIC DOPAMINE RECEPTOR SUBTYPE LIGANDS<br/>[FR] LIGANDS SPIROCYCLIQUES D'UN SOUS-TYPE DU RECEPTEUR DE LA DOPAMINE
申请人:PFIZER INC.
公开号:WO1998008835A1
公开(公告)日:1998-03-05
(EN) This invention relates to novel, pharmaceutically active compounds of formula (I) wherein a, b and R1 through R6 are defined as in the specification. These compounds exhibit central dopaminergic activity and are useful in the treatment of CNS disorders.(FR) L'invention concerne de nouveaux composés pharmaceutiquement actifs, de formule (I), dans laquelle a, b et R1 à R6 sont tels que définis dans la spécification. Ces composés ont une activité dopaminergique centrale et sont utiles dans le traitement des troubles du système nerveux central.
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US11203592B2
公开(公告)日:2021-12-21
The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20210221806A1
公开(公告)日:2021-07-22
The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.